Abstract 1831P
Background
The co-existence of cardiovascular disease (CVD) in cancer patients may explain treatment and outcomes disparities. However, CVD prevalence in cancer patients is unknown. We described CVD prevalence in adults with curable tumours and investigated factors associated with CVD.
Methods
From the UK National Cancer Registration and Analysis Service we retrieved data on patients with stage I-III breast cancer (BC), stage I-III colon/rectal cancer (CC/RC), stage I-III prostate cancer (PC), stage I-IIIA non-small cell lung cancer (NSCLC), stage I-IV diffuse large B cell lymphoma (DLBCL) and stage I-IV Hodgkin lymphoma (HL) in England in 2013-2018. We identified CVD from Hospital Episode Statistics and National Institute for Cardiovascular Outcomes Research datasets. We investigated CVD rates in tumour cohorts and evaluated the impact of patient and disease characteristics on its prevalence.
Results
Among 640,958 patients, mean age was 67.2 years, 47.5% of patients were male, 66.0% had Index of Multiple Deprivation (IMD) 1-3 and 46.7% Charlson comorbidity index (CCI) 0.104,035 (16.2%) had CVD. Men, older patients and those with higher CCI, more advanced stage cancer or higher IMD had higher CVD rates. After age- and sex-standardisation, prevalence was highest for NSCLC (36.2%) and lowest for BC patients (7.8%). After adjustment for age, sex, IMD and CCI, CVD odds were highest in NSCLC patients vs the other cohorts. NSCLC patients had the highest prevalence of ischaemic heart disease (21.8%), peripheral vascular disease (11.1%), congestive cardiac failure (8.5%), cerebrovascular disease (6.2%), valvular heart disease (6.1%), stroke (3.0%) and myocardial infarction (3.8%). BC patients had lower CVD category rates. Odds ratios (OR) of CVD were larger for each cohort compared to BC, particularly for NSCLC. After adjustment for age, sex, stage, IMD and CCI, all cohorts were significantly different to BC (OR 2.57; 95% CI 2.50, 2.64).
Conclusions
There is significant overlap between cancer and CVD although this varies between tumour types. CVD prevalence is key when comparing national and international treatment patterns and cancer outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Virtual Cardio-Oncology Research Institute.
Funding
Virtual Cardio-Oncology Research Institute.
Disclosure
N.M.L. Battisti: Financial Interests, Personal, Training: Lilly; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Training: Pfizer; Financial Interests, Personal, Speaker’s Bureau: AbbVie; Financial Interests, Personal, Training: Genomic Health. A. Ring: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Lilly. All other authors have declared no conflicts of interest.